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Background: The prognosis of human glioma is poor, and the highly invasive nature of the disease represents a
major impediment to current therapeutic modalities. The oncoprotein B-cell-specific Moloney murine leukemia virus
integration site 1 protein (Bmi-1) has been linked to the development and progression of glioma; however, the
biological role of Bmi-1 in the invasion of glioma remains unclear.
Methods: A172 and LN229 glioma cells were engineered to overexpress Bmi-1 via stable transfection or to be
silenced for Bmi-1 expression using RNA interfering method. Migration and invasiveness of the engineered cells
were assessed using wound healing assay, Transwell migration assay, Transwell matrix penetration assay and 3-D
spheroid invasion assay. MMP-9 expression and activity were measured using real-time PCR, ELISA and the gelatin
zymography methods. Expression of NF-kappaB target genes was quantified using real-time PCR. NF-kappaB
transcriptional activity was assessed using an NF-kappaB luciferase reporter system. Expression of Bmi-1 and MMP-9
in clinical specimens was analyzed using immunohistochemical assay.
Results: Ectopic overexpression of Bmi-1 dramatically increased, whereas knockdown of endogenous Bmi-1
reduced, the invasiveness and migration of glioma cells. NF-kappaB transcriptional activity and MMP-9 expression
and activity were significantly increased in Bmi-1-overexpressing but reduced in Bmi-1-silenced cells. The reporter
luciferase activity driven by MMP-9 promoter in Bmi-1-overexpressing cells was dependent on the presence of a
functional NF-kappaB binding site, and blockade of NF-kappaB signaling inhibited the upregulation of MMP-9 in
Bmi-1 overexpressing cells. Furthermore, expression of Bmi-1 correlated with NF-kappaB nuclear translocation as
well as MMP-9 expression in clinical glioma samples.
Conclusions: Bmi-1 may play an important role in the development of aggressive phenotype of glioma via
activating the NF-kappaB/MMP-9 pathway and therefore might represent a novel therapeutic target for glioma.
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Glioma is a common type of primary brain tumor and
represents one of the most aggressive and lethal human
cancer types [1]. Despite of enormous advances in surgi-
cal techniques and development of therapeutic agents,
the mortality of glioma remains high, with a cumulative* Correspondence: limf@mail.sysu.edu.cn
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reproduction in any medium, provided the or1-year survival rate lower than 30% [2,3]. The poor sur-
vival of glioma patients is largely attributed to the highly
invasive phenotype of glioma cells, which has been asso-
ciated with the widely recognized difficulty of perform-
ing complete surgical resection of gliomas [4]. At the
molecular level, tumor cell invasion is mediated by
sets of factors that initiate or promote cell motility,
matrix destruction, angiogenesis and other biological
events [5-8]. Matrix metalloproteinase-9 (MMP-9), a
member of the matrix metalloproteinase class of gelati-
nases, plays essential roles in the invasiveness of gliomatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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brane and extracellular matrix [9-11].
B-cell-specific Moloney murine leukemia virus integra-
tion site 1 protein (Bmi-1) acts as a repressor of the ex-
pression of certain genes by forming complexes with
multiple other Polycomb group (PcG) family members,
such as RING1, HPC2 and Mph2[12]. It has been
reported that Bmi-1 represses cells senescence by acetyl-
hydrolysis or deacetylhydrolysis of polycomb response
elements in chromosomes [13,14]. Numerous experi-
mental studies have indicated that Bmi-1 plays an im-
portant role in the development and progression of
cancer and essentially functions as an oncogene [15,16].
Knocking down Bmi-1 induces cell-cycle arrest and res-
cues the mRNA levels of tumor-suppressive p16INK4a,
homeobox A9 (HOXA9) and homeobox C13 (HOXC13)
genes [14,17]. In contrast, overexpression of Bmi-1 pre-
vents cancer cell apoptosis, possibly by activation of nu-
clear factor kappaB (NF-kappaB) pathway signaling [18].
Moreover, various studies have revealed that Bmi-1 is
required for the maintenance of the self-renewing prolif-
eration of several normal and cancer stem cells, includ-
ing neural crest stem cells and mammary stem cells
[19,20].
Aberrant activation of NF-kappaB is observed in vari-
ous types of human cancer, including glioma. Nuclear
localization of p65, an indicator of NF-kappaB activa-
tion, has also been demonstrated in clinical specimens
of glioblastoma multiform (GBM) [8,18,21]. The NF-
kappaB signialing orchestrates several key biological pro-
cesses during the development and progression of can-
cer by inducing transcription of a variety of target genes
that regulate cell proliferation, survival, invasion and
angiogenesis [8,18,22-25]. Inhibition of NF-kappaB acti-
vation enhances the radiosensitivity of human glioma
cells, and also inhibits the proliferation and invasiveness
of glioblastoma cells and glioblastoma-induced angio-
genesis [26,27]. Nevertheless, whether, and how, the bio-
logical functions of NF-kappaB is involved in the
oncogenic role of Bmi-1 remains obscure.
In the present study, we observed that overexpression
of Bmi-1 promoted, whereas knockdown of Bmi-1 inhib-
ited, the invasion and migration of glioma cells. We also
demonstrated that the ability of Bmi-1 to stimulate the
invasive phenotype in glioma cells was mechanistically
associated with activation of NF-kappaB and subsequent
upregulation and activation of MMP-9.
Methods
Cells and cell treatments
Glioma cell lines LN229 and A172 were grown in Dul-
becco’s modified Eagle’s medium (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS)
(HyClone, Logan, UT), 100 units penicillin and 100 unitsstreptomycin at 37°C in 5% CO2 atmosphere in a hu-
midified incubator. The MMP inhibitor and NF-kappaB
activation inhibitor II JSH-23 (EMD, La Jolla, CA) com-
pounds were dissolved in dimethyl sulfoxide (DMSO)
and used, respectively, at 50μM and 30μM. Treatment of
cells with the MMP inhibitor was performed for indi-
cated time lengths, and JSH-23 was used to treat cells
for 11 h.
Vectors and retroviral infection
pMSCV/Bmi-1 overexpressing human Bmi-1 was con-
structed as previously described [15]. To silence en-
dogenous Bmi-1 expression, Bmi-1 RNA interference
(RNAi) sequence (5’-ATGAAGAGAAGAAGGGATT-3’,
synthesized by Invitrogen) was cloned into retroviral
transfer vector pSuper-retro-puro. As described previ-
ously [28], retroviral particles were produced by cotrans-
fection with pSuper-retro-Bmi-1-shRNA and PIK
packaging plasmid into 293 T cells and collected 24 to
48 hrs after transfection to infect glioma cells. Stable cell
lines expressing Bmi-1 or with Bmi-1 silenced were
selected by treatment with 0.5 μg/ml puromycin for
10 days, beginning from 48 hours after infection [28].
After selection for 10–14 days, the cell lysates prepared
from the pooled population of cells in the sampling buf-
fer were fractionated on SDS-PAGE for immunoblotting
detection of Bmi-1 protein level.
Real-time RT-PCR and data analysis
Total cellular RNA was extracted using the Trizol re-
agent (Invitrogen) according to the manufacturer’s in-
struction. Two micrograms of RNA from each sample
were used for cDNA synthesis primed with random
hexamers. For PCR amplification of cDNA, an initial
amplification using gene-specific primers was done with
a denaturation step at 95°C for 10 minutes, followed by
28 cycles of denaturation at 95°C for 60 seconds, pri-
mer annealing at 58°C for 30 seconds, and primer ex-
tension at 72°C for 30 seconds. At completion of the
cycling, a final extension at 72°C for 5 minutes was
done before the reaction was terminated. Expression
levels of genes were normalized to housekeeping gene
GAPDH as the control. PCR primers were designed by
employing the Primer Express version 2.0 software (Ap-
plied Biosystems, Foster City, CA). The Primers was
shown as following: MMP9-up: ACGACGTCTTCCAG
TACCGA; MMP9-dn: TTGGTCCACCTGGTTCAACT;
CCND1-up: AACTACCTGGACCGCTTCCT; CCND1-
dn: CCACTTGAGCTTGTTC ACCA; Bcl-xL-up: ATTG
GTGAGTCGGATCGCAGC; Bcl-xL-dn: AGAGAAGGGGG
TGGGAGGGTA; TNF alpha-up: CCAGGCAGTCAGAT
CATCTTCTC; TNF alpha-dn: AGCTGGTTATCTCT
CAGCTCCAC; VEGFC-up: GTGTCCAGTGTAGATGAACTC;
VEGFC-dn: ATCTG TAGACGGACACACATG; MYC-up:





Western blotting analysis was performed according to
standard methods as previously described [18].The mem-
brane was probed with a 1:500-diluted rabbit anti-human
Bmi-1 antibody (Cell Signaling, Danvers, MA). The
membranes were stripped and re-probed with a mouse
anti-β-actin monoclonal antibody (1:1,000; Sigma, Saint
Louis, MI) as a loading control.
Wound healing assay
Cells were seeded on six-well plates with DMEM con-
taining 10% FBS and grown to confluence. The cells
were scratched with a sterile 200μL pipette tip to create
artificial wounds. At 0 and 24 hr after wounding, re-
spectively, phase-contrast images of the wound healing
process were photographed digitally using an inverted
Olympus IX50 microscope with 10× objective lens. Eight
images per treatment were analyzed to determine aver-
aging parameters of positioning of the migrating cells at
the wound edges by digitally drawing lines using the
Image-Pro Plus software (Media Cybernetics).
Transwell migration assay and Transwell matrix
penetration assay
Cells (1 × 104) to be tested were plated on the top side of
the polycarbonate Transwell filter without (for Transwell
migration assay) or with Matrigel coating (for Transwell
matrix penetration assay) in the upper chamber of the
BioCoatTM Invasion Chambers (BD, Bedford, MA) and
incubated at 37°C for 22 hrs, followed by removal of
cells inside the upper chamber with cotton swabs.
Migrated and invaded cells on the membrane bottom-
surface were fixed in 1% paraformaldehyde, stained with
hematoxylin, and counted (Ten random 200× fields per
well). Cell counts were expressed as the mean number
of cells per field of view. Three independent experiments
were performed and the data are presented as mean ±
standard deviation (SD).
3-D spheroid invasion assay
The Matrigel matrix (BD Biosciences, San Jose, CA) was
used in 3-D spheroid invasion assay, which displays
morphologies typical of highly aggressive invasiveness
presenting more outward projections (Invadopodia or
invasive feet) [29-33]. Indicated cells (1 × 104) were tryp-
sinized and seeded in 24-well plates coated with Matrigel
(2%, BD Biosciences), and medium was changed every
other day. Pictures were taken under microscope at 2-day
intervals for 2–3 weeks.Immunohistochemical analysis (IHC)
IHC was performed according to standard methods as pre-
viously described [28]. Sections were IHC analyzed using
anti-Bmi-1, anti-MMP-9 and anti-NF-kappaB antibodies
(Cell signaling, Danvers, MA,). Images were captured
using the AxioVision Rel.4.6 computerized image analysis
system (Carl Zeiss Co. Ltd., Jena).
Luciferase assay
Cells (1.5 × 104) were seeded in triplicates in 24-well
plates and allowed to settle for 24 hrs. One hundred
nanograms of luciferase reporter plasmid containing
fragments of the MMP-9 promoter with serial deletions,
pNF-kappaB-luc plasmid, or the control-luciferase plas-
mid, in combination with 1 ng of pRL-TK renilla plasmid
(Promega,Madison, WI), were transfected into glioma cells
using the Lipofectamine 2000 reagent (Invitrogen, Co.,
Carlsbad, CA) according to a protocol provided by the
manufacturer. Luciferase and renilla signals were mea-
sured at 48 h after transfection using the Dual Luciferase
Reporter Assay Kit (Promega, Madison, WI) according to
the manufacturer’s instruction. Three independent experi-
ments were performed and the data are presented as
mean±SD.
Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed using a commercial kit according
to the manufacturer’s manual (Keygentec, Shanghai).
Briefly, 100 μl of diluted standard and tested samples,
namely, Bmi-1-overexpressing or -silencing cells, and
the vector control cells, including a negative control,
were added to the ELISA plate and incubated at 36°C for
90 min. After the unbound samples were washed off by
DI water and PBS-Triton, specific antibody (anti-MMP-
9, anti-MMP-2, or anti-MMP-7) was incubated with the
plate at 36°C for 60 min. After further washing steps,
100 μl of second antibody was added and incubated for
60 min. Subsequently, the substrate was added and incu-
bated at RT for 60 min before the reaction was stopped,
followed by the results-reading with a microplate reader.
Colorimetric measurement was recorded as OD450
readings.
Gelatin zymography assay
Cells were seeded in 48-well culture plates at a density
of 3 × 104/well and incubated for 24 h before the
medium was replaced with serum-free medium (Invitro-
gen, Carlsbad, CA), followed by collection of condi-
tioned medium and quantification for protein contents.
Samples containing equal amounts of protein (1 μg/μl)
mixed with 4 × sampling buffer (3:1) were run on 9%
polyacrylamide gels containing 0.2% gelatin (Sigma,
Saint Louis, MI). After electrophoresis, the gel was
washed twice in wash buffer (2.5% Triton X-100, 50 mM
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followed by two rinses with the wash buffer (without
Triton X-100) and subsequent incubation at 37°C in
50 mM Tris–HCl (pH7.6), 5 mM CaCl2, 1 μM ZnCl2
and 0.02% Brij-35 for 16 h. The gels were stained with
0.1% Coomassie brilliant blue R-250 and then de-stainedFigure 1 Ectopic expression of Bmi-1 enhances the migration and inv
A172-vector, A172-Bmi-1, LN229-vector and LN229-Bmi-1 cells; β-actin was
expression were analyzed by densitometry quantification (lower). B, Wound
LN229-Bmi-1 cells. C, Representative micrographs (left) and quantification (
matrigel). D, Representative micrographs (left) and quantification (right) of
E, Representative micrographs from the three-dimensional spheroid invasio
were repeated at least three times with similar results. Vector: pMSCV-vecto
experiments; ** P< 0.01.with de-staining solution (40% methanol, 10% acetic acid
in distilled water). A protein marker was used to measure
the molecular weights of proteins in SDS-PAGE before
the staining and washing step of the Zymography Assay.
Meanwhile, the MMP-9 recombinant protein was also
used as the standard to confirm the band of MMP-9.asion of glioma cells. A, Western blot of Bmi-1 protein expression in
used as a loading control (upper). The fold changes of Bmi-1
healing assay of A172-vector, A172-Bmi-1, LN229-vector and
right) of cell migration in the Transwell migration assay (without
cell invasion in the Transwell matrix penetration assay (with matrigel).
n assay on the 4th day after cells were planted; these experiments
r. Error bars represent the mean± SD of three independent
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Paraffin-embedded, archived glioma specimens were
histopathologically diagnosed at the First Affiliated Hos-
pital of Sun Yat-sen University from 2000 to 2005. The
clinical information is described in Additional file 1:
Table S1. The use of the clinical specimens was approved
by the local Institutional Review Board, the Ethical Com-
mittee of the First Affiliated Hospital of Sun Yat-sen Uni-
versity, Guangzhou, Guangdong, China, and conformed
to the ethical guidelines of the Helsinki Declaration.
Statistical analysis
Statistical analyses were performed using the SPSS 11.0 stat-
istical software package. Data represent mean±SEM. P
values of 0.05 or less were considered statistically significant.
Results
Bmi-1 induced the aggressive phenotype in glioma
cells in vitro
To investigate the effect of Bmi-1 on the aggressiveness
of glioma cells, A172 and LN229 glioma cells stably
overexpressing Bmi-1 were established (Figure 1A).
Wound healing assays demonstrated that ectopic expres-
sion of Bmi-1 accelerated the migration of glioma cells
(Figure 1B). Transwell migration assay (without Matri-
gel) revealed that overexpression of Bmi-1 significantly
increased the rate of migration of A172 and LN229 gli-
oma cells, as compared with that of control cells
(Figure 1C). Furthermore, the Transwell matrix penetra-
tion assay (coated with Matrigel) showed that overex-
pression of Bmi-1 increased the invasive ability of both
glioma cell lines (Figure 1D). Strikingly, the 3-D spheroid
invasion assay demonstrated that Bmi-1-overexpressing
glioma cells displayed cellular morphologies typical of a
highly invasive phenotype, as the cells presented
increased numbers of outward projections compared to
the control cells (Figure 1E). Taken together, these dataFigure 2 Bmi-1 activates MMP-9 in glioma cells. A, Real-time PCR quan
Bmi-1-overexpressing cells (Bmi-1). MMP-9 expression levels are presented a
normalized to GAPDH. B, ELISA for secreted MMP-9 protein in cell superna
supernatants. Vector: pMSCV-vector. Error bars represent the mean± SD ofsuggested that overexpression of Bmi-1 promoted the
migration and invasiveness of glioma cells in vitro.
Bmi-1 increased MMP-9 expression and activity in
glioma cells
Numerous reports have mechanistically associated the
invasive ability of glioma cells with expression and acti-
vation of MMP-9 [34]. To understand the mechanism
by which overexpression of Bmi-1 promoted the inva-
siveness and migration of glioma cells, we investigated
the expression and activity of MMP-9 in A172 and
LN229 glioma cells stably overexpressing Bmi-1. As
shown in Figure 2A, MMP-9 mRNA expression was
upregulated in Bmi-1-overexpressing cells compared to
that in control cells. ELISA (Figure 2B) and the gelatin
zymography assay confirmed that overexpression of
Bmi-1 increased MMP-9 expression and activity in gli-
oma cells (Figure 2C). Taken together, these data sug-
gested that overexpression of Bmi-1 upregulated and
activated MMP-9 in glioma cells in vitro.
Silencing Bmi-1 reduced glioma cell invasiveness and
MMP-9 expression
To construct an experimental model in which endogenous
Bmi-1 expression was silenced, Bmi-1 RNA interference
(RNAi) sequences were cloned into the retroviral transfer
vector pSuper-retro-puro, and retroviral production and
infection were performed as previously described [18].
Western blotting confirmed that Bmi-1 protein expression
was silenced in glioma cells transduced with pSuper-retro-
puro-Bmi-1-RNAi retroviral vector (Figure 3A). Knocking
down endogenous Bmi-1 dramatically reduced the migra-
tion and invasion of A172 and LN229 cells, and induced
immotile and spheroid morphology (Figure 3B-E). Knock-
down of Bmi-1 also significantly decreased the expression
and activity of MMP-9 in glioma cells when compared
with vector-control cells (Figure 4A-C).tification of MMP-9 mRNA expression levels in vector-control cells and
s the fold changes relative to that in vector-control cells and
tants. C, Gelatin zymography assay of MMP-9 gelatinase activity in cell
three independent experiments; ** P< 0.01.
Figure 3 Knockdown of Bmi-1 reduces the migration and invasion of glioma cells. A, Western blot analysis of Bmi-1 protein expression in
vector-control cells and Bmi-1-shRNA-transduced glioma cell lines (Bmi-1-RNAi); β-actin was used as a loading control (upper). The fold changes
of Bmi-1 expression were analyzed by densitometry quantification (lower). B, Wound healing assay of vector-control cells and Bmi-1-shRNA-
transduced glioma cell lines. C, Representative micrographs and quantification of cell migration in the Transwell migration assay (without
matrigel). D, Representative micrographs and quantification of cell invasion in the Transwell matrix penetration assay (with matrigel). E,
Representative micrographs from the three-dimensional spheroid invasion assay on the 4th day after cells were planted. The experiments were
repeated for at least three times with similar results. RNAi-Vector: pSuper-retro-puro-vector. Error bars represent the mean± SD of three
independent experiments; ** P< 0.01.
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NF-κB pathway
We previously reported that Bmi-1 promoted NF-
kappaB activation in glioma [18]. In the current study,
we assessed the impact of Bmi-1 on NF-kappaB tran-
scriptional activity in A172 and LN229 glioma cellsusing a luciferase reporter assay. As shown in Figure 5A,
overexpression of Bmi-1 increased, whereas silencing of
Bmi-1 inhibited the luciferase activity of the NF-kappaB
reporter gene. As activation of NF-kappaB induces the
transcription of a variety of NF-kappaB target genes, we
performed semi-quantitative RT-PCR analysis to
Figure 4 Knockdown of Bmi-1 transcriptionally downregulates MMP-9 expression and activity. A, Quantification MMP-9 mRNA expression
levels in control cells and Bmi-1 RNAi-transfected cells; normalized to β-actin. B, ELISA quantification of MMP-9 protein in cell supernatants.
C, Gelatin zymography assay of MMP-9 gelatinase activity in cell supernatants. RNAi-Vector: pSuper-retro-puro-vector. Error bars represent the
mean± SD of three independent experiments; ** P< 0.01.
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get genes, including CCND1, BcL-XL, TNF-α, VEGF-C
and MYC, in Bmi-1-overexpressing, -silenced and vector
control-glioma cells. Compared to vector control-cells,
overexpression of Bmi-1 upregulated the transcription of
NF-kappaB target genes; whereas knockdown of Bmi-1
downregulated these target genes (Figure 5B).
Moreover, the luciferase activity of a reporter gene
driven by the MMP-9 promoter containing the NF-
kappaB binding site increased significantly in Bmi-1-
overexpressing cells and decreased in Bmi-1-silenced
cells. Mutating the NF-kappaB binding site in the MMP-9
promoter abrogated luciferase activity, and a MMP-9 pro-
moter fragment lacking the NF-kappaB binding site dis-
played no significant change in the luciferase activity in
Bmi-1 overexpressing glioma cells (Figure 5C). Taken to-
gether, these results indicated that Bmi-1 promoted the
transactivation activity of the NF-kappaB binding site
present in theMMP-9 promoter in glioma cells.
Bmi-1 induced aggressiveness in glioma cells via the NF-
kappaB/MMP-9 pathway
Next, we examined whether Bmi-1 increased the aggres-
siveness of glioma cells via activation of the NF-kappaB sig-
naling pathway. The increased migratory and invasive
ability of Bmi-1-overexpressing glioma cells were dramatic-
ally reversed by treatment with JSH-23, a specific NF-
kappaB inhibitor that reduces the transcriptional activity of
NF-kappaB, and these effects were accompanied by a re-
duction in MMP-9 expression (Figure 6A-D). These data
suggested that functional activation of NF-kappaB was es-
sential for the highly invasive phenotype induced in glioma
cells by Bmi-1. Moreover, the invasivenes of Bmi-1-
overexpressing glioma cells could be abrogated by an
MMP-9 inhibitor, suggesting that MMP-9 played an im-
portant role in mediating Bmi-1-induced invasion of gli-
oma cells (Figure 6A-D). Moreover, when we furtherexamined the effect of Bmi-1 on the expression levels of
MMP-2 and MMP-7 in A172 and LN229 glioma cells, our
result showed that neither overexpressing nor silencing
Bmi-1 had any an effect on the mRNA and protein levels
of MMP-2 or MMP-7 (Additional file 2: Figure S1), impli-
cating that MMP-9 might be a major mediator for Bmi-1
mediated invasiveness of glioma cells.
Collectively, these results indicated that the overexpres-
sion of Bmi-1 induced an aggressive phenotype in glioma
cells by activating NF-kappaB signaling, leading to the
upregulation of the NF-kappaB target gene MMP-9.
Clinical relevance of Bmi-1 triggered NF-kappaB/MMP-9
activation in human gliomas
Lastly, we examined whether the NF-kappaB-activating ef-
fect of Bmi-1 in glioma cells found in our in vitro tests was
clinically relevant. IHC analysis of 127 cases of clinical
human glioma specimens revealed that upregulation of
Bmi-1 was associated with in an upregulation of MMP-9
and nuclear localization of NF-kappaB (Figure 7A). Correl-
ation studies in glioma specimens showed that Bmi-1 ex-
pression significantly correlated with the expression of
MMP-9 (P<0.01). Our results also exhibited that Bmi-1
expression and NF-kappaB nuclear localization were statis-
tically correlated (Figure 7B, P<0.01). Collectively, all these
results further supported the notions that Bmi-1 induced
MMP-9 expression, and that such effects involved activat-
ing NF-kappaB signaling.
Discussion
The key finding of this study is that Bmi-1 may induce an
aggressive phenotype in glioma via modulation of the NF-
kappaB signaling. Previous studies have indicated that
Bmi-1 is overexpressed and associated with poorer overall
survival in glioma [18]. Our current study used glioma cell
lines expressing intermediate levels of endogenous Bmi-1
as an experimental model, and by examining the effect of
Figure 5 (See legend on next page.)
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Figure 5 Bmi-1 induces NF-kappaB transcriptional activity. A, Luciferase reporter assay of NF-κB transcriptional activity in vector-control, Bmi-
1 overexpressing (Bmi-1) and Bmi-1 silenced glioma cells (Bmi-1-RNAi). B, Real-time PCR analysis of NF-κB-regulated gene expression in vector-
control, Bmi-1 overexpressing and Bmi-1 silenced glioma cells; GAPDH was used as the control gene. C, Left, schematic illustration of luciferase
reporter gene construction using cloned fragments of the human MMP-9 promoter. Right, transactivation activity of luciferase reporter genes
driven by MMP-9 promoter fragments (as indicated on the left) in vector-control, Bmi-1 overexpressing and Bmi-1 silenced glioma cells. Luciferase
activity was normalized to Renilla luciferase activity. Vector: pMSCV-vector, RNAi-Vector: pSuper-retro-puro-vector. Error bars represent the
mean± SD of three independent experiments; * P< 0.05, ** P< 0.01.
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topic Bmi-1, on the phenotype of glioma cells, we have
identified that Bmi-1 activates NF-kappaB and subse-
quently upregulates MMP-9 expression, leading to
increased migration and invasion of glioma cells.
As a member of the PcG family, Bmi-1 is overexpressed
in various tumor types, including acute myeloid leukemia,
lung cancer, ovarian cancer, nasopharyngeal carcinoma,
breast cancer and colon cancer, suggesting that Bmi-1
represents a potential oncogene [16,35-39]. Furthermore,
p16INK4a and p14ARF are targets of Bmi-1 suppressionFigure 6 Bmi-1 promotes an aggressive phenotype in glioma cells via
Bmi-1-overexpressing cells were treated with a NF-kappaB inhibitor JSH-23
migration in the Transwell assay (without matrigel). B, Quantification of cel
C, Representative micrographs of the 3-D spheroid invasion assay. The exp
D, ELISA analysis of MMP-9 secretion. Error bars represent SD of three inde[40,41], and Bmi-1 has been found to promote cell prolif-
eration by suppressing the p16/Rb and/or p14ARF/MDM2/
p53 pathways [42,43]. Upregulation of Bmi-1 also induces
the epithelial-mesenchymal transition (EMT), enhances
the aggressiveness of human nasopharyngeal carcinoma
cells and stabilizes Snail, a transcriptional repressor asso-
ciated with EMT, via modulation of the PI3K/Akt/GSK-3β
pathway [16]. Moreover, it has been reported that Bmi-1
can downregulate transcription of the tumor suppressor
phosphatase and tensin homolog deleted on chromosome
ten (PTEN) via a direct association with the PTEN geneactivation of the NF-kappaB-MMP-9 pathway.
at 30μM or MMP-9 inhibitor at 50μM. A, Quantification of cell
l invasion in the Transwell matrix penetration assay (with matrigel).
eriments were repeated for at least three times with similar results.
pendent experiments; ** P< 0.01.
Figure 7 Clinical relevance of Bmi-1 expression in human gliomas. A, Bmi-1 levels in association with MMP-9 and NF-kappaB expression in
127 primary human glioma specimens. Two representative cases, diagnosed as WHO grade I (upper row) and grade III (lower row), are shown.
The insets are enlarged images derived from the original pictures. B, Percentages of all specimens (upper) and specimens in grade IV (lower)
showing low- or high-Bmi-1 expression relative to the levels of MMP-9 and nuclear or cytoplasmic NF-kappaB p65 localization, analyzed by
IHC staining.
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lates the NF-kappaB/MMP-9 signaling pathway to mediate
an aggressive phenotype in human glioma, suggesting that
Bmi-1 may represent a potential therapeutic target for the
treatment of glioma.
Activating mutations or amplification of oncogenes, such
as epidermal growth factor receptor (EGFR) and phospha-
tidylinositol 3-kinase (PI-3 K), or loss of function in tumor
suppressor genes, such as p53 and PTEN, are involved in
oncogenesis and the progression of glioma. The molecular
mechanisms that mediate the aggressive phenotype in gli-
omas, however, are incompletely understood [44-46]. Fur-
thermore, it is now well recognized that the low survival
rate of glioma patients can be largely attributed to the
highly invasive nature of glioma cells, which results in the
destruction of surrounding brain tissue, and the invasive-
ness of glioma cells correlates with patient prognosis
[2,3,44-47]. Most current therapies for the treatment ofglioma are ineffective against invading cells.
Characterization of the molecular mechanisms mediating
invasion may provide a foundation for the development of
new anti-glioma strategies. MMP-9, one member of the
MMP family, is upregulated and associated with progres-
sion and poor prognosis in glioma [8]. Interestingly, nu-
merous genes that promote the aggressiveness of glioma,
including astrocyte elevated gene-1 (AEG-1), are also
involved in the modulation of MMP-9 transcription [48].
Furthermore, multiple transcription factor-binding sites
have been characterized in the upstream regulatory region
of the MMP-9 gene, including binding sites for the AP-1
and NF-kappaB transcription factors [8,49,50]. Moreover,
AP-1 and NF-kappaB transcription factors can induce ex-
pression and activation of MMP-9 by interacting with
these binding sites, and consequently promote tumor pro-
gression [48,51]. The present study demonstrates that
Bmi-1 induces MMP-9 expression and activity via a
Jiang et al. BMC Cancer 2012, 12:406 Page 11 of 12
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blocking the activity of NF-kappaB drastically reduces the
pro-invasive effect of Bmi-1 and preventes upregulation of
MMP-9. Taken together, our data provide new insights in
the development of novel strategies to prevent tumor inva-
sion in glioma by inhibiting the expression of Bmi-1.
Conclusions
In conclusion, this study demonstrates that Bmi-1 is upre-
gulated and promotes an aggressive phenotype in glioma
via activation of the NF-kappaB signaling pathway, leading
to increased MMP-9 expression and activity. Bmi-1 may
therefore represent a potential therapeutic target for
improved treatment of human gliomas.
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